G
Gamida Cell
Develops solutions in the fields of cell and immune therapy
About Gamida Cell
Gamida Cell is a biopharmaceutical company focused on developing advanced cell therapies to treat cancer and rare blood diseases. Operating within the biotechnology sector, Gamida Cell primarily serves healthcare providers and patients in need of innovative treatment options. The company’s core product, Omidubicel, is an advanced cell therapy designed to enhance the success of bone marrow transplants. Gamida Cell generates revenue through the development and commercialization of its proprietary therapies, which are currently in various stages of clinical trials. The company’s business model involves extensive research and development, followed by regulatory approval and market introduction. Gamida Cell aims to address unmet medical needs by leveraging its expertise in cell therapy and immunotherapy. The company’s market includes hospitals, clinics, and specialized healthcare institutions that perform bone marrow transplants and treat hematologic malignancies. By focusing on groundbreaking clinical research and strategic partnerships, Gamida Cell strives to bring life-saving therapies to patients worldwide.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 1998
- Headquarters
- Jerusalem, Israel
- Listing
- IPO 2018
- Employees
- 93
- Open positions
- None listed
- Dealroom signal
- 68.7/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Verification, Risk Management, Biotechnology, Oncology, Stem Cells, Autoimmune, Regenerative Medicine, Spinout, Hospital, Metabolism
- Business model
- Manufacturing
- Client focus
- b2b
Latest news
Press, funding announcements and product moves mentioning Gamida Cell.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| POST IPO DEBTDebt | Dec 2022 | $25M | — | Highbridge Capital Management | ↗ |
| POST IPO DEBTDebt | Feb 2021 | $75M | — | Highbridge Capital Management | — |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
| Year | Revenue | Growth | EBITDA | Margin |
|---|---|---|---|---|
| 2026 | $1.8M | 0% | −$70M | -3915.2% |
| 2025 | $1.8M | 0% | −$70M | -3915.2% |
| 2024 | $1.8M | 0% | −$70M | -3915.2% |
| 2023 | $1.8M | — | −$70M | -3915.2% |
| 2022 | $0 | — | −$75M | — |
| 2021 | $0 | — | −$87M | — |
| 2020 | $0 | — | −$60M | — |
Growth signals
Latest recorded traffic for Gamida Cell is 1.9K monthly website visits, down 9.5% over the last three months. Gamida Cell's team declined 1.1% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
Israeli Ministry of Economy and Industry
Series A2 investors entered at this stage
Auriga Partners (Paris)
Auriga Partners
Series B and later11 investors entered at this stage
IHCV- BIBiomedical Investments
Teva
Denali Ventures
Amgen
Clal Biotechnology Industries
Shavit Capital
Israel Biotech Fund
Novartis Venture Fund- VGVMS Investment Group
- HMHighbridge Capital Management
Other known investors1 additional known investor
Hadassah Medical Center
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Gamida Cell on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Gamida Cell’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.